Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”

Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”

Targeted immune checkpoint blockade augments anti-tumor immunity and induces durable responses in patients with melanoma and other solid tumors. It also induces specific “immune-related adverse events” (irAEs). IrAEs mainly include gastrointestinal, dermatological, hepatic and endocrinological toxic...

Full description

Bibliographic Details
Main Authors: Lucia Gelao, Carmen Criscitiello, Angela Esposito, Aron Goldhirsch, Giuseppe Curigliano
Format: Article
Language:English
Published: MDPI AG 2014-03-01
Series:Toxins
Subjects:
checkpoint-blocking antibodies
immune response
toxicity
immune therapies
ipilimumab
Online Access:http://www.mdpi.com/2072-6651/6/3/914

Internet

http://www.mdpi.com/2072-6651/6/3/914

Similar Items